Drugs / 68Ga-DOTA-MGS5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06155994 | Jan 2021 → Jun 2023 | neuroendocrine neoplasm | Medical University Innsbruck | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-DOTA-MGS5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06155994 ↗ |
| Known as | DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH2 | “A prospective phase 1/2a pilot study (NCT06155994) was performed at our center to compare the diagnostic performance of cholecystokinin-2 receptor (CCK2R) PET/CT imaging with...” PMID 40876951 ↗ Oct 2025 |
| Modality | Peptide | “the 68Ga-labeled peptide analog” PMID 40876951 ↗ Oct 2025 |
| Route | Intravenous | “intravenous administration” NCT06155994 ↗ |